NCT04720001

Florbetaben PET Imaging in PPA

Florbetaben PET Imaging in Primary Progressive Aphasia

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 1 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 100 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to better understand how dementia affects activity in different parts of the brain.

Detailed description

This study will examine Positron Emission Tomography (PET) imaging with Florbetaben F18. Florbetaben F18 is a radioactive tracer that binds to particles in your brain. This process displays activity in the brain. Florbetaben F18 is a PET amyloid imaging agent approved by the United States Food and Drug Administration (FDA) to estimate the amount of beta-amyloid plaque in adult patients who are being evaluated for Alzheimer's disease and other causes of cognitive decline. The purpose of this research is to better understand how dementia affects activity in different parts of the brain. Currently, the scientific community is limited by how well it can see inside the brain. The use of a PET scan better helps us understand what the brain looks like in a diseased state. Participation in the study will help to understand what brain activity looks like, especially around language regions.

Conditions

• Primary Progressive Aphasia
• Alzheimer Disease

Interventions

Type	Name	Description
DRUG	Florbetaben F18	A single injection of 8.1mCi of florbetaben F18 will be administered by intravenous bolus injection
DEVICE	PET	PET Scan for brain imaging

Timeline

• Start date: 2018-08-23
• Primary completion: 2021-01-21
• Completion: 2021-02-26
• First posted: 2021-01-22
• Last updated: 2024-10-16

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study